Espey MG. Measurement of plasma volume using fluorescent silica-based nanoparticles. J Appl Physiol 112: 681-687, 2012. First published December 15, 2011 doi:10.1152/japplphysiol.01068.2011 is an important determinant of cardiovascular function and organ perfusion, and it is the target of infusion and diuretic therapies in daily clinical practice. Despite its fundamental importance PV is not commonly measured because available methods of tracer dilution are reliant on dye substances that suffer from numerous drawbacks including binding plasma proteins, spectral changes, and clearance kinetics that complicate analysis and interpretation. To address these issues, we have tested the utility of fluorescent nanoparticles comprised of a dye-rich silica core and polyethylene glycol-coated shell. Photophysical and visual analysis showed discrete size-gradated nanoparticle populations could be synthesized within a distribution tolerance of Ϯ4 nm, which were optically unaffected in the presence of plasma/ albumin. In normal mice, the cutoff for renal filtration of nanoparticles from blood into urine was Յ11 nm. A linear relationship between body weight and PV was readily determined in mice administered far red fluorescent nanoparticles sized either 20 or 30 nm. PV measurements using nanoparticles were correlated to values obtained with Evans blue dye. Induced expansion or contraction of PV was demonstrated with albumin or furosemide administration, respectively, in mice. Longitudinal experiments Ͼ30 min required matched untreated control mice to correct for nanoparticle loss (Ϸ30%) putatively to the reticuloendothelial/phagocyte system. Collectively, the findings support a nanotechnology-based solution to methodological problems in measure of PV, notably in clinical settings where information on hemodynamic changes may improve treatment of injury and disease. dye tracer; albumin; dilution technique A LONG-STANDING CHALLENGE in clinical medicine has been the need for safe, simple, and reliable methods for the direct measurement of plasma volume (PV). Although PV is only ϳ25% of total extracellular fluid, it is the fluid component whose magnitude is directly regulated by afferent and efferent control mechanisms. Plasma volume-activated vascular receptors initiate afferent pathways that lead to changes of neurohormonal regulators like the renin-angiotension-aldosterone axis or the sympathetic nervous system. Under normal conditions these effector systems minimize alterations of PV and thereby of extracellular fluid volume by regulating renal sodium and water excretion (11). Nevertheless, deviations from normovolemia occur in response to many physiological and pathological insults, and these deviations of PV can be of profound importance for blood pressure regulation and organ perfusion by altering vascular, cardiac, renal, hepatic, immune, and endocrine endpoints (1, 9, (12) (13) (14) (15) 21) .
A LONG-STANDING CHALLENGE in clinical medicine has been the need for safe, simple, and reliable methods for the direct measurement of plasma volume (PV). Although PV is only ϳ25% of total extracellular fluid, it is the fluid component whose magnitude is directly regulated by afferent and efferent control mechanisms. Plasma volume-activated vascular receptors initiate afferent pathways that lead to changes of neurohormonal regulators like the renin-angiotension-aldosterone axis or the sympathetic nervous system. Under normal conditions these effector systems minimize alterations of PV and thereby of extracellular fluid volume by regulating renal sodium and water excretion (11) . Nevertheless, deviations from normovolemia occur in response to many physiological and pathological insults, and these deviations of PV can be of profound importance for blood pressure regulation and organ perfusion by altering vascular, cardiac, renal, hepatic, immune, and endocrine endpoints (1, 9, (12) (13) (14) (15) 21) .
Clinical investigations of PV have been largely reliant on tracer dilution approaches where an intravascular injection of a known quantity of tracer is followed by the measurement of tracer concentration in plasma after equilibration, generally known as Fick's principle. The assumption that steady-state conditions exist in vivo is an inherent caveat. In a clinical setting, the goal of PV measurements would be to quantify the degree of departure from normovolemic equilibrium. Common dye tracers such as indocyanine green and Evans blue become useful indicators of PV because of their binding to plasma proteins, chiefly albumin, after intravascular injection (3, 8, 14, 20) . However, protein binding changes the optical properties of the dye, confounding an accurate determination of the actual concentration of tracer at the time of administration, necessitating the need for theoretical extrapolations to account for the kinetics of this initial binding/mixing. Moreover, these computational difficulties are compounded by concurrent processes of free dye and protein-bound dye clearance from the vasculature as governed by transvascular permeability in the kidney, liver and other systems.
In this work, we have tested whether precisely sized nanoparticles could be utilized to measure PV. Nanoparticles were comprised of a silica spheroid core containing fluorescent dye, surrounded by a polyethylene glycol coated shell. We examined the physical and optical properties of the nanoparticles and tested their validity in assessing PV in models of plasma expansion and contraction in mice.
METHODS
Nanoparticles. Synthesis of the amorphous silica nanoparticles was performed as from methods published elsewhere (17, 19, 22) using reactive derivatives of the organic dye Cy5 (GE Healthcare) and atto647 (Atto-Tec GmbH) which exhibit an emission maximum above 650 nm, and atto590 (Atto-Tec GmbH), which exhibits emission maximum above 610 nm. After synthesis, all Cy5 nanoparticles were coated with a polyethylene glycol (PEG) of molecular mass ϳ0.5 kDa, and atto590 and atto647 nanoparticles were coated with PEG with 5 kDa molecular mass according to methods previously described (2, 5) . Post coating, the nanoparticles were purified by dialysis into ultrapure deionized water via 10-kDa molecular mass cutoff membranes to remove unreacted free dyes and PEG molecules. Stock solutions of nanoparticles were prepared in sterile water and kept at 4°C in the dark until use.
Fluorescence correlation spectroscopy (FCS).
The samples, after purification by dialysis, were diluted into deionized water for FCS measurements, such that the number of particles in the focal volume was less than ten. FCS measurements were performed at room temperature on a custom instrument based on single-photon 633-nm laser excitation. Excitation light was focused with Olympus 60ϫ water immersion objective (NA ϭ 1.2), and emission was collected through the same objective. The fluorescence was separated from the excitation with a Chroma Technology 633RPC dichroic mirror and passed through a Chroma Technology HQ650LP emission filter to a photon-counting Perkin Elmer SPCM-HQRH-14 avalanche photodiode. The resulting photocurrent was digitally autocorrelated with a Hamamatsu M9003 counting board.
Atomic force microscopy (AFM). Stock atto647 nanoparticle solutions were diluted 10 times in ultrapure, deionized water (Millipore) and a 3 l drop was incubated for 10 min on freshly cleaved mica disks. The samples were then gently rinsed with 400 l ultrapure, deionized water and dried in a nitrogen stream. Imaging was performed in noncontact (tapping) mode on the Bioscope-Catalyst AFM (Bruker Nano-surfaces, Santa Barbara, CA) using silicon probes with nominal resonance frequencies of either ϳ75 kHz or ϳ300 kHz, with nominal stiffness of ϳ2.8 N/m or ϳ42 N/m, respectively. Highresolution images were analyzed using image processing software (NIH ImageJ) to estimate particle dimensions and volumes.
Visible spectroscopy and fluorimetry. Evans Blue dye (Sigma) absorbance (optical density, OD) was determined at 620 nm on a spectrophotometer (Hewlett Packard 8453). Nanoparticle fluorescence in microsamples (1 l) was determined at appropriate wavelengths on a Nanodrop fluorometer (Thermo Scientific). In the absence of nanoparticles, no fluorescence was observed in plasma; however, intermittent mouse urine samples would occasionally display a nominal autofluorescence peak at ex/em 647/667. For larger sample volumes, fluorescence measurements were performed by using FluostarOptima plate reader (BMG Labtech).
Mice and in vivo instrumentation. Animal care and experimentation were approved by the Animal Care and Use Committees at the NIDDK and University of Utah in accordance with National Institutes of Health principles as outlined in their Guide for the Care and Use of Laboratory Animals. Mice were either C57BL/6J or FVB wild-type mice maintained on standard rodent chow and tapwater ad libitum.
Plasma volume was measured by tracer dilution technique using either nanoparticles or Evans blue dye. Concentration of each stock tracer was determined by regression analysis of either fluorescence (nanoparticles at appropriate wavelengths) or absorbance (Evans Blue OD at 620 nm) after serial dilution in mouse plasma, which gave a RFU/l value for nanoparticle stock suspensions and OD/l value for Evans blue dye solution (5 g/l).
Conscious mice received nanoparticles via a single bolus injection of suspension (100 g in 50 l of saline) into the tail vein while briefly restrained. Seven minutes after tail vein injection, whole blood samples were collected from the submandibular vein. To examine the relationship between body weight and PV, mouse weight was recorded immediately prior to analysis. Evans blue and nanoparticles were directly compared by sequential administration in the same subject. Mice were briefly administered isoflurane and given an initial bolus injection of Evans blue dye (100 g in 20 l saline) into the retroorbital sinus. At 10, 30, and 60 min postinjection, whole blood samples were collected from the tail vein. Each mouse subsequently received a single bolus injection of nanoparticles (50 g in 10 l saline) into the retroorbital sinus and whole blood samples were collected from the tail vein at 10, 30, and 60 min postinjection.
For fully instrumented mice, mice were induced with an intraperitoneal injection of thiobutabarbital (100 mg/kg) and subcutaneous injection of ketamine (100 mg/kg). Mice were placed on a servocontrolled heating pad that kept core body temperature at 38°C by means of rectal probe feedback. The trachea was cannulated and a minimal stream of O2 was directed toward the tracheal cannula. The left carotid artery was catheterized with hand-drawn polyethylene tubing for continuous measurement of arterial blood pressure and blood withdrawal. The jugular vein was catheterized for the injection of nanoparticle suspensions (500 g in 100 l saline) as a single bolus followed by saline flush (50 l). Whole blood (15 l) was collected from the arterial line into heparinized microcapillary hemotocrit tubes (Fischer), and plasma was immediately separated by centrifugation. The effect of blood loss from repeated sampling on hematocrit and PV was negligible and within the level of both intra-and interindividual variability. Urine was continuously collected through a polyethylene catheter inserted into the bladder. No adverse effects were observed consequent to infusion of nanoparticles. Mice were euthanized at the conclusion of each experiment.
Plasma expansion and contraction. An expansion of PV was achieved through intravenous injection of bovine serum albumin (BSA, 2.25%, 250 l; Sigma) 30 min post nanoparticle injection. Contraction of PV was induced by intravenous injection of furosemide (40 mg/kg) immediately following injection of nanoparticles. In each case, control experiments were performed in littermate mice that were matched in all components with the exception of not receiving either BSA or furosemide.
Statistics. Individual data points were taken as the mean of triplicate measurement values from the same sample. For control and treatment groups of mice, these individual values were averaged and expressed as arithmetic mean Ϯ standard deviation (SD); n refers to the number of mice examined per group. Statistical analysis for AFM was performed using OriginLab (Northampton, MA). GraphPad Prism (5.0, La Jolla, CA) was used for all other statistical analyses and graphing.
RESULTS

Fluorescence correlation spectroscopy (FCS).
The molecular dynamics of nanoparticles in solution was characterized by FCS. Atto647 fluorophore was tested in the form of free dye, dye encapsulated in a Si-based nanoparticle core, or as nanoparticle core festooned with a methoxy-capped polyethylene glycol (PEG, 5 kDa) shell. FCS curves for each species fit to a single diffusion coefficient, representative of a monodispersed population of single nanoparticles in solution. The brightness properties were determined from the mean rate of photons counted within the focal volume of an equivalent concentration of each dye/particle species (Fig. 1A) . The stepwise increase in brightness of the core and complete nanoparticle relative to equivalent free dye, respectively, relates to the increased quantum efficiency of photon emission from dye molecules when restricted within the nanoparticle core.
The FCS lag time associated with the amplitude of the normalized correlation curve of fluorescence emanating from these dye/particle materials provided information on hydrodynamic radius. The FCS diffusion coefficient of free Atto647 dye molecules was 0.25 m 2 /ms. Incorporation of equivalent dye molecules into Stöber colloidal silica nanoparticle cores increased the diffusion coefficient 7-fold to 1.84 m 2 /ms, while coating of the solvent shell with PEG further increased values to 4.52 m 2 /ms. In accord with the Stokes-Einstein function of a molecule diffusing in an optically defined volume, the hydrodynamic radius for each species was determined (Fig. 1B) . The mean radius for the complete "30 nm" diameter nanoparticle was 15.2 Ϯ 0.6 nm (ϮSD). These FCS data were consistent with a low degree of size variation for both the fluorescent core structure and the complete PEG-shell nanoparticle amid their respective monodispersed populations.
Atomic force microscopy (AFM)
. Nanoparticles were directly visualized by AFM to further delineate size distribution within the nanoparticle preparation. PEG-coated Atto647 nanoparticles were dried onto mica disks and imaged by atomic force microscopy with nanoscale resolution (Fig. 2 ). Using probes with resonance frequencies of either 75 or 300 kHz , the mean diameter of nanoparticles was 30.8 Ϯ 3.9 nm or 30.6 Ϯ 4.2 nm, respectively, which were fit to a single Gaussian size distribution (Fig. 2, B and C) . Although a structured water hydration layer of 3-10 Å remains on/within the nanoparticle after drying for AFM imaging, an apparent occasional association of nanoparticles was observed ( Fig. 2A) . Despite this possible processing artifact, AFM data overall were in excellent agreement with the hydrodynamic radius derived by FCS, confirming the tight size tolerance within the population.
Spectral interference with plasma protein. The effect of albumin on the spectral signals obtained with either Evans blue dye or nanoparticles was examined. Suspension of atto647 (30 nm) nanoparticles into buffer containing albumin (0 to 10% wt/vol) had a negligible effect on fluorescence. However, Evans blue dye absorbance decreased as albumin concentration was increased (Fig. 3A) . Relative to buffer alone, Evans blue absorbance was decreased Ϸ50% in a 10% albumin solution, consistent with previous studies (20) showing spectral changes associated with the dye binding to albumin. A similar effect was observed upon dilution (1:2) of Evans blue dye solution into normal human plasma which decreased dye absorbance by 19.2 Ϯ 0.2% (ϮSD, n ϭ 3; Fig. 3B ). In contrast, dilution of atto647 (30 nm) nanoparticles into plasma had little impact on fluorescence beyond the nominal variance observed with the microfluorometer.
Renal clearance of nanoparticles. The nominal variance in size observed under both FCS and AFM (Figs. 1B and 2 ) suggested that distinct nanoparticle preparations would either be cleared or retained in the bloodstream based on their PLASMA VOLUME MEASUREMENT permeation through the kidney. To establish the size cutoff for renal clearance of nanoparticles, a series of Cy5-labeled nanoparticles of 3-, 6-, 11-, 18-, and 25-nm diameters were synthesized. Individual mice received a single intravenous bolus of a specific sized nanoparticle preparation via jugular vein catheter, and urine was collected from the bladder at both 10 and 40 min postinjection. As shown in Fig. 4 , 40% of the fluorescence at the 3-nm size level was recovered in the urine within 10 min of injection into the bloodstream. After 40 min, Ϸ65 % of the total fluorescence administered had been recovered in the urine. With 6-nm sized nanoparticles, appearance of fluorescence in the urine was substantially decreased: only 6 -7% of total injected fluorescence was recovered after 10 and 40 min. At the 11-nm size, nanoparticles were barely detectable in the urine, summated to 1.3 Ϯ 0.5% at 40 min postinjection. For nanoparticles Ն18 nm, Ͻ1% of the total fluorescence administered intravenously could be detected in urine. A similar lack (Ͻ1%) of clearance into urine was observed for atto590 20 nm and atto647 30 nm nanoparticle preparations for periods of up to 1 h post-intravenous injection (data not shown). Collectively, these data show that the renal filtration cutoff for permeation of uncharged nanoparticles from the blood into the urine was likely Ϸ12 nm. Importantly, particle sizes of Ն18 nm were not lost from the bloodstream by filtration through the kidney into the urine.
Determination of plasma volume. Characterization of nanoparticles showed that fluorescence was neither quenched nor spectrally shifted by the presence of plasma proteins. This finding suggested that fluorescent nanoparticles may be a suitable tracer to estimate PV based on Fick's principle. An essential parameter of the tracer dilution technique is the concentration of tracer at the time of injection. A linear relationship between concentration and fluorescence was evident for nanoparticles in plasma (Fig. 5A, atto647 30 Having foreknowledge of RFU 0 , PV could be readily determined from a single blood sample withdrawn only a few minutes after of administration of a precise volume of nanoparticles. PV data shown in Fig. 5B was obtained 5-7 min postinjection. These data show an expected linear relationship between PV and mouse body weight (m ϭ 53 Ϯ 3.4, r 2 ϭ 0.968, n ϭ 11; Fig. 5B ). Similar data were obtained in mice injected with atto590 (20 nm) nanoparticles m ϭ 56 Ϯ 8.4, r 2 ϭ 0.919, n ϭ 6 (data not shown). PV was determined in mice by sequential administration of Evans blue and nanoparticles to directly compare data obtained with each tracer in the same subject (Fig. 5C ). Pairwise analysis showed that PV values obtained with either tracer were significantly correlated (Pearson r ϭ 0.854; P Ͻ 0.001; n ϭ 4 mice, 12 data pairs). Nanoparticle sequestration over time. Accurate estimation of PV using the tracer dilution technique is greatly facilitated by retention in the circulatory system. Having determined that nanoparticles Ն 18 nm were not eliminated from the blood by urinary excretion (Fig. 3) , changes in fluorescence were examined in serial plasma samples obtained from normal anesthetized mice over a period of 2 h following nanoparticle admin- istration. Fluorescence values from plasma samples obtained up to 30 min postinjection were constant (Fig. 6) . However, measurements at 1 and 2 h postinjection showed reductions of plasma fluorescence by 31 and 34%, respectively.
Plasma expansion or contraction. The effect of albumin on PV was examined in normal mice (30 -35 g) (Fig. 7) . Blood samples obtained 30 min after administration of atto647 (30 nm) nanoparticles showed PV of 1,000 Ϯ 51 l. Intravenous bolus injection of BSA solution (2.25%) produced an increase in PV to 1,462 Ϯ 385 l after 30 min. When these data were adjusted to account for putative reticuloendothelial-macrophage-mediated nanoparticle loss over the 1-h experimentation period, the corrected PV was increased 1.9-fold to 1,915 Ϯ 505 l (ANOVA P Ͻ 0.01).
The effect of furosemide on PV was examined in normal mice. No differences in absolute fluorescence values were observed in plasma samples collected from mice over a 2-h period post administration of furosemide (40 mg/kg iv). However, when these data were normalized against plasma RFU obtained at each time point from untreated control mice, PV contraction with furosemide was evident showing a PV decrease of Ϸ30% from 1,278 l to 900 and 863 l at 1 and 2 h, respectively (Fig. 8) .
DISCUSSION
Because of its fundamental importance for the maintenance of blood pressure and organ perfusion an assessment of PV is central to fluid management in patients, most notably in acute care situations (e.g., trauma, shock, sepsis, stroke). Nevertheless, because actual PV measurements are cumbersome and A: concentration versus fluorescence plot for atto647 30 nm nanoparticles diluted in mouse plasma. B: blood was collected 7 min after conscious male mice received a single intravenous bolus of atto647 30 nm nanoparticles via tail vein injection. Line: linear regression; n ϭ 11. C: blood samples were collected from the tail vein 10, 30, and 60 min after conscious male mice (n ϭ 4) received a single intravenous bolus of nanoparticles (atto590 20 nm) via retroorbital sinus. Each mouse subsequently received a single intravenous bolus of Evans Blue dye (EB) and blood was collected from the tail vein after 10, 30, and 60 min. Shown are pairwise plasma volume (PV, nanoparticle versus EB) for all time points (n ϭ 12 data pairs). Line: linear regression. Closed symbols indicate individual data points, n ϭ 4 mice. Fig. 7 . Effect of albumin on plasma volume expansion. Anesthetized mice received a single intravenous bolus of nanoparticle saline suspension (atto647 30 nm, 61.5 g in 100 l, 50 l saline flush) via jugular vein catheter at time zero and whole blood (15 l) was collected at the time points indicated. Arrow: mice received bovine serum albumin (BSA, 2.25% in 250 l iv). Data are expressed as mean plasma volume Ϯ SD present (triplicate measures/time; n ϭ 4 mice). **ANOVA P Ͻ 0.01 30 min post-BSA vs. pre-BSA. Adjusted: post-BSA data were normalized Ϸ ϩ30% for tracer loss over 1 h time course (see Fig. 6 ).
unreliable, physicians are often forced to infer PV from indirect hemodynamic indicators. Determination of PV using conventional dye tracer substances has been hampered by the inherent binding interactions between the dye and plasma proteins such as albumin (14, 15) . Theoretical extrapolations must be made to estimate the concentration of tracer at the time of injection, to estimate the initial intravascular kinetics of tracer distribution, and lastly, to estimate loss of tracer into the extravascular parenchyma and urine. Therefore, conventional dye tracers are intrinsically in flux with albumin and susceptible variability during the measurement period dependent on a range of pathological forces, making interpretation of these data in relation to a clinical picture problematic.
In the present study we have examined the utility of watersoluble nanoparticles comprised of a far red fluorescent dye core covalently bound to an amorphous silica matrix and surrounded by a methoxy-terminated PEG shell (5, 19) . Changes in the optical spectral qualities of nanoparticles were not evident upon mixture with either purified albumin or plasma, in contrast to traditional tracer substances such as Evans blue (Fig. 3) . Photophysical characterization by FCS showed that the nanoparticle architecture enhanced fluorescence brightness relative to free dye (Fig. 1A) . The further brightness enhancement observed with complete PEG-coated nanoparticles may be due to the protection the PEG shell affords the encapsulated dye molecules from interaction with the solvent averting potential dissipation of nonphotonic energy (19) . While encapsulation of far red fluorescent dyes (Cy5, atto590, atto647) in the current study abrogated potential optical interferences from nanoparticles suspended in biological fluids, the Stöber colloidal silica process is readily amenable to incorporation of infrared dyes into the nanoparticle core paving an avenue for in vivo imaging development.
Application of Fick's principle to determine PV ideally requires perfect retention of tracer in the vascular bed prior to the time of sample acquisition. Loss of tracer from the plasma compartment after intravenous injection would create an artifactual increase in PV. A given nanoparticle population was homogeneous and spheroid in shape with a relatively tight size distribution. For instance, 30-nm-diameter nanoparticles were uniform to Ϯ1.2 and Ϯ4 nm as assessed by FCS and AFM, respectively (Figs. 1B and 2 ). This enabled stepwise size series experiments in normal mice to examine apparent in vivo nanoparticle dilution independent of PV. The diameter cutoff for clearance of nanoparticles by the kidneys was found to be between 6 and 11 nm (Fig. 4) , consistent with previous studies (5, 7) . Furthermore, a large body of data indicates that macromolecules and specifically neutral dextrans with effective molecular diameters greater than about 8 -9 nm are retained by the glomerular capillary filter (4, 16) . In contrast to larger nanoparticles, a portion of the 3-nm sized nanoparticles (Ϸ35%, Fig. 4 ) putatively underwent extrarenal clearance from the vasculature into the interstitial fluid, akin to rapid escape of freely filtered dye tracer complexes (15, 23) . The combined lack of association with albumin ( Fig. 3) and vascular retention properties at 20 -30 nm (Fig. 4) exemplify the prospective superiority of fluorescent amorphous silica nanoparticles over conventional dye tracers for PV measurements.
Experiments conducted with 30-nm fluorescent nanoparticles demonstrated that reliable and facile determination of PV could be conducted within Ϸ5 min following a single injection (Fig. 5B) . As expected, PV varied as a linear function of body weight (r 2 ϭ 0.968) amounting to ϳ4% of body weight. Although PV values obtained using nanoparticles were well correlated with those acquired by the Evans blue technique (Pearson r ϭ 0.828, Fig 5C) , several important distinctions are noteworthy. Nanoparticle RFU 0 obtained by interpolating fluorescence in either plasma (Fig. 5A ) or HEPES buffer (50 mM, not shown) was indistinguishable. These data contrast sharply with the spectral changes associated with Evans blue and other conventional dye tracers in the presence of plasma proteins ( Fig. 3; 14, 20) . Initial Evans blue free dye concentration at the time of injection (OD 0 ) could only be estimated by extrapolation of OD values taken at multiple time points back to zero. Therefore, the lack of a true zero when combined with confounders particularly in pathogenic circumstances where albumin is in flux render conventional dye tracers ill-suited for application in a variety of clinical conditions.
Fluorescence recovery of 30-nm nanoparticles in plasma was stable in normal mice for up to 30 min post-intravenous administration (Fig. 6) . However, plasma fluorescence decreased by ϳ30% at 1 and 2 h postinfusion, while urine remained without fluorescence. These data likely reflect nanoparticle removal via the reticuloendothelial-macrophage system leading to eventual hepatobiliary excretion or other vascular components over extended (Ն30 min) periods of time, consistent with greater rate of loss observed with matched non-PEG-coated nanoparticles (data not shown) and prior studies (5, 6, 10, 18) . The PEG shell of the complete nanoparticle serves to alter the surface hydrophobicity and net charge characteristics thereby reducing the potential for elimination from the plasma by nonspecific binding of the endothelial glycocalyx (14) , aggregation due to opsonization, and phagocytosis (6, 10, 18) . FCS data fit to a single diffusion coefficient (Fig 1B) , indicative of a population of single monodispersed nanoparticles. However, an apparent minor population of associated nanoparticles was visible by AFM (Fig 2A) . While agglomeration may be an artifact attributable to sample dehydration, it cannot be completely ruled out that some clusters were present in aqueous solution and plasma. The dimension (Ͻ100 nm) of such putative clusters in vivo would be insufficiently sized to cause emboli. Moreover, clusters may present Fig. 8 . Effect of furosemide on plasma volume contraction. Anesthetized mice received a single intravenous bolus of nanoparticles saline suspension (atto647 30 nm, 61.5 g in 100 l, 50 l saline flush) via jugular vein catheter at time zero and whole blood (15 l) was collected at the time points indicated. Mice received furosemide (40 mg/kg iv) at time zero. Adjusted: data were normalized Ϸ ϩ30% for tracer loss in untreated control mice (n ϭ 4) at each corresponding time point (see Fig. 6 ) and are expressed as means Ϯ SD (triplicate measures/time; n ϭ 2). a better target for opsonization and phagocytosis by the RESmacrophage system relative to single monodispersed nanoparticles.
Collectively, our data show that optimally sized (e.g., 20 -30 nm) PEG-coated fluorescent nanoparticles are suitable for straightforward assessment of PV by single measurements in blood collected within 30 min of tracer administration. Therefore, the effect of a gene, disease, or chronic treatment on PV relative to a control group could be determined. Furthermore, our data show that acutely induced PV changes can be examined longitudinally in the same subject. PV expansion or contraction from baseline following administration of either BSA or furosemide, respectively, was consistently observed (Figs. 6 and 7) . To compensate for putative loss of tracer to the reticuloendothelial-macrophage system over longer periods of time (notably Ͼ30 min), PV values need to be normalized relative to untreated control mice at matched time points. Clinical translation of these nanoparticles into longitudinal PV measurement (e.g., Ͼ30 min postadministration) will require studies to establish the biodistribution and lifetime of nanoparticles in human subjects.
In conclusion, these findings support a nanotechnologybased solution to methodological problems that sully current efforts to measure PV. PV homeostasis is a major underpinning of fundamental physiology. Measurements of the dynamic changes in PV that occur in response to injury and disease can provide important insight to clinicians. The current work suggests that inert biocompatible nanoparticle tracers can fulfill the unmet need for a safe, simple, and reliable method to determine PV.
